At a Glance
- Companies: Novartis; SciNeuro Pharmaceuticals
- Location: Basel, Switzerland (Novartis); Rockville, MD/Shanghai (SciNeuro)
- Deal value: $165m upfront; up to $1.5bn milestones; tiered royalties
- Focus area: Next‑generation amyloid beta antibody with blood–brain barrier shuttle
- Next steps: Joint early development; Novartis leads later stages and global commercialisation
What happened?
Novartis has entered a global licensing and collaboration agreement with SciNeuro Pharmaceuticals for an exclusive worldwide licence to its de novo amyloid beta antibody programme incorporating proprietary blood–brain barrier shuttle technology. SciNeuro receives $165 million upfront plus research funding and is eligible for up to approximately $1.5 billion in total milestones and tiered royalties on net sales.
Why does it matter?
The antibody is engineered to selectively bind toxic amyloid‑beta aggregates while sparing non‑pathogenic forms, potentially offering improved efficacy and safety over existing anti‑amyloid therapies like Leqembi and Kisunla. Combined with SciNeuro’s shuttle technology for enhanced brain penetration, the programme aims for disease modification in Alzheimer’s, addressing limitations of first‑generation antibodies.
Who’s behind it?
SciNeuro specialises in neurodegenerative diseases and BBB biology, with its Lp‑PLA2 inhibitor SNP318 already in clinic. Novartis is expanding neuroscience through bolt‑on deals, including this and its planned $12bn Aity Biosciences acquisition.
How was it achieved?
The partners will co‑develop through early preclinical and initial clinical stages, with Novartis providing research support. Novartis then assumes full responsibility for later development, regulatory submissions and global commercialisation, while SciNeuro retains economic participation via milestones and royalties.
What’s next?
Closing is expected H1 2026 pending antitrust clearance, with early data potentially advancing the lead candidate into larger trials. Success would position Novartis as a multi‑modality Alzheimer’s player.
What are people saying?
SciNeuro CEO Dr Liisa Selin highlighted the partnership’s potential to “redefine Alzheimer’s treatment paradigms”. Novartis Neuroscience Head Shreeram Aradhye called it a key addition to its “robust neuroscience portfolio”.